Canfosfamide

Summary

Canfosfamide (CHEMBL2111086) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Chemistry: 787.5 Da · C26H40Cl4N5O10PS

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2111086
Name	Canfosfamide
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	5312109
Molecular formula	C26H40Cl4N5O10PS
Molecular weight	787.5
InChIKey	OJLHWPALWODJPQ-QNWVGRARSA-N

SMILES: C1=CC=C(C=C1)[C@H](C(=O)O)NC(=O)[C@H](CS(=O)(=O)CCOP(=O)(N(CCCl)CCCl)N(CCCl)CCCl)NC(=O)CC[C@@H](C(=O)O)N

IUPAC name: (2S)-2-amino-5-[[(2R)-3-[2-[bis[bis(2-chloroethyl)amino]phosphoryloxy]ethylsulfonyl]-1-[[(R)-carboxy(phenyl)methyl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid

Also known as: Canfosfamida, Canfosfamide, CANFOSFAMIDE

Parent form; salt/anhydrous children: CHEMBL2107319

Patent coverage: 429 distinct patent families (1,184 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).